Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Eledon’s quarter ended September 30, 2026.
Eledon Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Eledon’s quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s quarterly financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue-free biotech posted a $21.0M operating loss excluding warrant revaluation, highlighting continued cash burn ahead of Phase 3
- Cash, equivalents and short-term investments $69.7M, funding operations into Q2 2027 but likely requiring additional financing afterward
- Global Phase 3 LEGACY kidney-transplant trial targeted for Q4 2026, expected enrollment approximately 600 patients
- FDA Fast Track for kidney transplantation and IND clearance for an islet-transplant registrational study reduce regulatory friction for tegoprubart
- Phase 2 data showed eGFR 71 vs 58 mL/min/1.73m² at month 24 and zero vs seven rejection events versus tacrolimus, supporting differentiation but requiring Phase 3 validation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eledon Pharmaceuticals, Inc. 8-K filings
Get the next ELDN 8-K as it lands
Follow ELDN for push alerts, or ask the research agent what this filing means.